FAMPYRA® (fampridine)   

- first treatment indicated to improve walking in adults with MS1


FAMPYRA is indicated for the improvement of walking in adult patients with MS and walking disability (EDSS 4–7)1 . See the SmPC for contraindications.


The recommend dosage for FAMPYRA is one 10 mg tablet, twice daily, taken twelve hours apart, taken without food.1


FAMPYRA improves walking speeds across all types of MS.2

Safety profile

Urinary tract infection is a very common adverse reaction to FAMPYRA (frequency ≥1/10). Other adverse reactions are mostly neurological and include seizure, insomnia, anxiety, balance disorder, dizziness, paraesthesia, tremor, headache and asthenia.
For contraindications and special warnings and precautions for use, which cover seizure risk, renal impairment and hypersensitivity reactions, please see the FAMPYRA SmPC.1

See the SmPC (UK | ROI) and PI for more information


FAMPYRA is a potassium channel blocker and is the only therapy licensed to treat walking impairment in MS.1


Study design: MS-F202, MS-F203, MS-F204: A pooled analysis of three double-blind, randomised, placebo-controlled trials in adult patients (aged 18-70) with clinically definite MS. The objective was to evaluate the effects of baseline demographic, disease characteristics and concomitant therapy on the efficacy of FAMPYRA.

Abbreviations: EDSS: expanded disability status scale; MS: multiple sclerosis 

MSP-PAN-0010f Date of prep: September 2018